Mild Cognitive Impairment (dementia) Market Increasing geriatric population; rising incidence rates of mild cognitive impairment (dementia) patients are expected to augment the market at a healthy CAGR of 5.64% during the forecast period, 2022 to 2032

Market Research Future (MRFR) has published on the “Global mild cognitive impairment Market”.

The mild cognitive impairment market is estimated to register a CAGR of 5.64% during the forecast period of 2023 to 2032.

Mild Cognitive Impairment Market Highlights

The global mild cognitive impairment market is expected to register a CAGR of 5.64% during the forecast period and is estimated to reach USD 3.29 billion by 2032.

The global mild cognitive impairment market is experiencing growth due to the rising prevalence of mild cognitive impairment worldwide and increasing awareness surrounding this condition. The increasing prevalence of mild cognitive impairment (MCI) globally is serving as a significant catalyst for the expansion of the global MCI treatment market. For instance, in October 2023, the University of Southern California (US) reported that approximately eight million Americans are suffering from mild cognitive impairment. Furthermore, in January 2024, CORDIS revealed that more than 10 million Europeans show MCI. Also, in March 2022, Karolinska Institute stated that more than one fourth of the older population in rural China was affected by MCI. Moreover, one of the major factors contributing to mild cognitive impairment is the growing geriatric population. As per the Alzheimer’s Association 2022 report, nearly 12% to 18% of people aged 60 or older are living with MCI in America.

Despite this, challenges such as polypharmacy and managing comorbidities may hinder market expansion. Nonetheless, the development of advanced technologies for early MCI diagnosis is expected to open profitable prospects for the market.

Key Players

MRFR recognizes the following companies as the key players in the mild cognitive impairment market— Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG, Switzerland), AbbVie Inc. (US), Biogen (Switzerland), Eisai Co., Ltd.  (JAPAN), Aurobindo Pharma (India), Sun Pharmaceutical Industries Ltd (India), Teva Pharmaceutical Industries Ltd. (Israel), Taj Pharmaceuticals Limited (India).

Segment Analysis

The mild cognitive impairments market has been segmented based on disease type, age and indication and treatment.

On the basis of the disease type, the market is segmented into amnestic MCI, and non-amnestic MCI. The amnestic MCI segment dominated the market in 2022 and is projected to be the fastest-growing during the forecast period, 2023–2032. Amnestic mild cognitive impairment (MCI) is a subtype of MCI characterized by memory deficits beyond what is expected for a person's age but not severe enough to meet the criteria for dementia. Individuals with amnestic MCI typically exhibit memory impairment that is greater than expected for their age and educational level but do not show significant impairments in other cognitive domains such as language, executive function, or visuospatial skills. Amnestic MCI is considered a transitional stage between normal aging and dementia, particularly Alzheimer's disease. Research suggests that individuals with amnestic MCI have an increased risk of progressing to Alzheimer's disease or other forms of dementia compared to those without cognitive impairment.

On the basis of the age, the market is segmented into child, adults, and geriatric. The geriatric segment dominated the market in 2022 and adult is projected to be the fastest-growing during the forecast period, 2023–2032. Mild Cognitive Impairment (MCI) in geriatric individuals, particularly those aged 65 and older, is a common concern in clinical settings. For instance, globally, the prevalence of cognitive impairment in individuals aged 50 years or older ranges from 5.1 to 41.0%, with a median of 19.0%. In children, mild cognitive impairment may manifest as difficulties in learning, memory, attention, executive functions, or language skills. Some potential causes include genetic factors, prenatal exposure to toxins or infections, perinatal complications, traumatic brain injury, neurodevelopmental disorders like autism spectrum disorder or attention deficit hyperactivity disorder (ADHD), and certain medical conditions affecting brain development.

On the basis of the indication, the market is segmented into Lewy body dementia, Parkinson’s disease dementia, Alzheimer’s disease, vascular dementia, and others. The market in 2022 was dominated by the Alzheimer's disease segment, while Parkinson's disease dementia is expected to experience the highest growth rate during the forecast period of 2023-2032. Alzheimer's disease is a progressive neurodegenerative disorder that primarily impacts memory, cognition, and behaviour. It is the leading cause of dementia among older adults, with over 6 million Americans of all ages affected by it. As of 2023, approximately 6.7 million Americans aged 65 and older were living with Alzheimer's, with 73% of them being 75 years or older. Around one in every nine adults aged 65 and older (10.7%) are affected by Alzheimer's.

On the basis of treatment, the market is segmented into medication and therapy. The medication segment dominated the market in 2022 and therapy is projected to be the fastest-growing during the forecast period, 2023–2032. Cognitive impairment can arise from different underlying conditions, including Alzheimer's disease, vascular dementia, and mild cognitive impairment. The choice of treatment depends on the cause and severity of the impairment. Cognitive Stimulation Therapy (CST) is a scientifically supported psychosocial intervention that aims to enhance cognitive function, quality of life, and overall well-being in individuals with cognitive impairment, particularly those with dementia. Typically conducted in a group setting, CST involves a range of activities and discussions that aim to stimulate cognitive abilities and promote social interaction.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Mild Cognitive Impairment Market Research Report

Regional Analysis

The mild cognitive impairment market, based on region, has been divided into North America, Europe, Asia-Pacific, and Rest of the World. North America consists of US and Canada. The Europe mild cognitive impairment market comprises of Germany, France, the UK, Italy, Spain, and the rest of Europe. The mild cognitive impairment market Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The rest of the mild cognitive impairment service providers market comprises of the Middle East, Africa, and Latin America.

The market for mild cognitive impairment in North America has the most share (42.60%) in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 4.97% to reach over USD 1.31 billion by 2032. Mild cognitive impairment market has a bright future in North America, with steady expansion predicted. Further market expansion is anticipated as a result of investments in healthcare infrastructure and rising public awareness of modern medical treatments. The growing technology improvements, both established businesses and newcomers are well-positioned to take advantage of these opportunities and address the growing need for better surgical results.

The Europe’ market are currently undergoing substantial growth, driven by a confluence of factors that include technological advancements, an aging population, and a mild cognitive impairment. This dynamic landscape is witnessing notable innovations in mild cognitive impairment solutions, leading to enhanced efficacy and improved outcomes. The improvement in mild cognitive impairment ultimately leads to enhanced patient care. This transformative journey aligns with broader goals of advancing healthcare technologies and ensuring better outcomes, positioning Europe as a key player in the global market and contributing to the ongoing enhancement of healthcare delivery and patient well-being across the continent.

Furthermore, the Asia-pacific mild cognitive impairment market accounted for USD 0.40 billion in 2022 and is projected to grow at a CAGR of 6.91% during the forecast period. The Asia pacific mild cognitive impairment’ market is projected to experience significant growth in the coming years. factors such as the increasing number of cognitive impairments, rising prevalence of chronic diseases, and technological advancements are expected to drive market growth. the market is also being expanded by the aging population, who are more likely to consume capsules for treatment.

The market for mild cognitive impairment in the rest of the world was valued at USD 0.13 billion in 2022 and is expected to grow with a compound annual growth rate (cagr) of 3.72%. the rest of the world market is divided into middle east, Africa, and Latin America. Mild cognitive impairment market is on rise due to increasing awareness. Furthermore, the development of advanced technologies and continuous product innovation are driving the growth of the market, improving the overall effectiveness of medical solutions. in these regions, where the healthcare infrastructure is changing quickly, the government support is also improving the healthcare infrastructure.

Key Findings of the Study

• The mild cognitive impairments market is expected to reach USD 3.29 billion by 2032, at a CAGR of 5.64% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market.


• Based on disease type, the Amnestic MCI segment was attributed to holding the largest market in 2023.


• Johnson & Johnson Services, Inc. (US), Pfizer Inc. (US), Novartis AG (Switzerland), AbbVie Inc. (US), Biogen (Switzerland) are some top key players.